Safety and Immunogenicity of an FhSAMS Vaccine Against Fasciola hepatica in Dairy Cattle

ABSTRACT Fasciolosis is a parasitosis of great importance for livestock, as well as for public health, as it is considered by the WHO as a neglected disease. Disease control is complex and reinfections make the use of therapeutic products an unsustainable method from an economic, environmental and h...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Parasite Immunology. - 46(2024), 11
1. Verfasser: Viana, Kelvinson Fernandes (VerfasserIn)
Weitere Verfasser: Sperandio, Natânia do Carmo, Neto, Felipe Berbari, Donatele, Dirlei Molinari, Souza, Adrieli Barboza, Santos, Angelo Gabriel Vidal, Rivas, Açucena Veleh, Barcellos, Ema Carolina de Almeida, Martins, Isabella Vilhena Freire
Format: Online-Aufsatz
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Parasite Immunology
Umfang:8
LEADER 01000naa a22002652 4500
001 WLY020262329
003 DE-627
005 20241127092347.0
007 cr uuu---uuuuu
008 241127s2024 xx |||||o 00| ||und c
024 7 |a 10.1111/pim.13074  |2 doi 
028 5 2 |a 2024-11-27_PIM_2024_46_11.zip.xml 
035 |a (DE-627)WLY020262329 
035 |a (WILEY)PIM13074 
040 |a DE-627  |b ger  |c DE-627  |e rda 
100 1 |a Viana, Kelvinson Fernandes  |e verfasserin  |4 aut 
245 1 0 |a Safety and Immunogenicity of an FhSAMS Vaccine Against Fasciola hepatica in Dairy Cattle 
264 1 |c 2024 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a © 2024 John Wiley & Sons Ltd. 
520 |a ABSTRACT Fasciolosis is a parasitosis of great importance for livestock, as well as for public health, as it is considered by the WHO as a neglected disease. Disease control is complex and reinfections make the use of therapeutic products an unsustainable method from an economic, environmental and health point of view. The aim of this study was to evaluate a new vaccine formulation for dairy cattle, containing soluble Fasciola hepatica antigens associated with Montanide 763 AVG and saponin adjuvants (FhSAMS). The vaccine was tested with two protocols, a single dose and a booster dose 6 months after the first dose. The FhSAMS vaccine proved to be safe, with no side effects. Furthermore, it was able to generate a more robust humoral immune response when a six‐month booster dose was used, in addition to stimulating greater production of IFN‐ʏ, indicating a Th1 profile immune stimulus. 
700 1 |a Sperandio, Natânia do Carmo  |4 aut 
700 1 |a Neto, Felipe Berbari  |4 aut 
700 1 |a Donatele, Dirlei Molinari  |4 aut 
700 1 |a Souza, Adrieli Barboza  |4 aut 
700 1 |a Santos, Angelo Gabriel Vidal  |4 aut 
700 1 |a Rivas, Açucena Veleh  |4 aut 
700 1 |a Barcellos, Ema Carolina de Almeida  |4 aut 
700 1 |a Martins, Isabella Vilhena Freire  |4 aut 
773 0 8 |i Enthalten in  |t Parasite Immunology  |g 46(2024), 11  |w (DE-627)WLY012322709  |x 13653024  |7 nnns 
773 1 8 |g volume:46  |g year:2024  |g number:11  |g extent:8 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_WLY 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_21 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_60 
912 |a GBV_ILN_70 
912 |a GBV_ILN_110 
912 |a GBV_ILN_121 
912 |a GBV_ILN_206 
912 |a GBV_ILN_350 
912 |a GBV_ILN_618 
912 |a GBV_ILN_2001 
912 |a GBV_ILN_2005 
912 |a GBV_ILN_2008 
912 |a GBV_ILN_2009 
912 |a GBV_ILN_2018 
912 |a GBV_ILN_2035 
912 |a GBV_ILN_2105 
951 |a AR 
952 |d 46  |j 2024  |e 11  |g 8